Related references
Note: Only part of the references are listed.Overall survival results for durvalumab and savolitinib in metastatic papillary renal cancer.
Cristina Suarez Rodriguez et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Efficacy of Savolitinib vs Sunitinib in Patients With MET-Driven Papillary Renal Cell Carcinoma The SAVOIR Phase 3 Randomized Clinical Trial
Toni K. Choueiri et al.
JAMA ONCOLOGY (2020)
Cabozantinib (C) in combination with atezolizumab (A) in non-clear cell renal cell carcinoma (nccRCC): Results from cohort 10 of the COSMIC-021 study
B. A. McGregor et al.
ANNALS OF ONCOLOGY (2020)
Nivolumab plus cabozantinib vs sunitinib in first-line treatment for advanced renal cell carcinoma: First results from the randomized phase III CheckMate 9ER trial
T. K. Choueiri et al.
ANNALS OF ONCOLOGY (2020)
First-line pembrolizumab (pembro) monotherapy for advanced non-clear cell renal cell carcinoma (nccRCC): Results from KEYNOTE-427 cohort B.
David F. McDermott et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study
Nieves Martinez Changa et al.
LANCET ONCOLOGY (2019)
Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update
Toni K. Choueiri et al.
EUROPEAN JOURNAL OF CANCER (2018)
Characterization of Clinical Cases of Advanced Papillary Renal Cell Carcinoma via Comprehensive Genomic Profiling
Sumanta K. Pal et al.
EUROPEAN UROLOGY (2018)
Crizotinib achieves long-lasting disease control in advanced papillary renal-cell carcinoma type 1 patients with MET mutations or amplification. EORTC 90101 CREATE trial
Patrick Schoffski et al.
EUROPEAN JOURNAL OF CANCER (2017)
Biomarker-Based Phase II Trial of Savolitinib in Patients With Advanced Papillary Renal Cell Cancer
Toni K. Choueiri et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Everolimus Versus Sunitinib Prospective Evaluation in Metastatic Non-Clear Cell Renal Cell Carcinoma (ESPN): A Randomized Multicenter Phase 2 Trial
Nizar M. Tannir et al.
EUROPEAN UROLOGY (2016)
The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part A: Renal, Penile, and Testicular Tumours
Holger Moch et al.
EUROPEAN UROLOGY (2016)
Everolimus versus sunitinib for patients with metastatic non-clear-cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial
Andrew J. Armstrong et al.
LANCET ONCOLOGY (2016)
Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma
W. Marston Linehan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
First-line treatment with sunitinib for type 1 and type 2 locally advanced or metastatic papillary renal cell carcinoma: a phase II study (SUPAP) by the French Genitourinary Group (GETUG)
A. Ravaud et al.
ANNALS OF ONCOLOGY (2015)
Axl receptor tyrosine kinase is a potential therapeutic target in renal cell carcinoma
H. Yu et al.
BRITISH JOURNAL OF CANCER (2015)
Volitinib, a potent and highly selective c-Met inhibitor, effectively blocks c-Met signaling and growth in c-MET amplified gastric cancer patient-derived tumor xenograft models
Paul R. Gavine et al.
MOLECULAR ONCOLOGY (2015)
MET Is a Potential Target across All Papillary Renal Cell Carcinomas: Result from a Large Molecular Study of pRCC with CGH Array and Matching Gene Expression Array
Laurence Albiges et al.
CLINICAL CANCER RESEARCH (2014)
The International Society of Urological Pathology (ISUP) Vancouver Classification of Renal Neoplasia
John R. Srigley et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2013)
Phase II and Biomarker Study of the Dual MET/VEGFR2 Inhibitor Foretinib in Patients With Papillary Renal Cell Carcinoma
Toni K. Choueiri et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
A Phase 2 Trial of Sunitinib in Patients with Advanced Non-clear Cell Renal Cell Carcinoma
Nizar M. Tannir et al.
EUROPEAN UROLOGY (2012)
Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth
F. Michael Yakes et al.
MOLECULAR CANCER THERAPEUTICS (2011)
An orally available small-molecule inhibitor of c-met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms
Helen Y. Zou et al.
CANCER RESEARCH (2007)
Share Paper
